RUNX1‑RUNX1T1 (AML1‑ETO) Translocation, t(8;21)
Also known as: RUNX1-RUNX1T1 Translocation, RUNX1-RUNX1T1 Fusion, AML1-ETO Translocation, AML1-ETO Fusion
Use
The (8;21) translocation occurs in approximately 5% of AML. These cases are usually considered core‑binding factor AML (CBF‑AML). The translocation is usually associated with a high rate of complete remission and longer overall survival in AML subtype M2. This assay is recommended for diagnostic confirmation of and for monitoring minimal residual disease (MRD) and predicting relapse. For monitoring MRD, we recommend monitoring trend rather than the absolute value of a single measurement.
Special Instructions
Note: Test is RNA‑based. Please select Extract & Hold ‑ RNA if specimen hold service is desired.
Limitations
Not provided.
Methodology
PCR‑based (RT‑PCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube
Storage Instructions
Use cold pack for transport; ship same day as drawn whenever possible.